Expert Review of Anticancer Therapy

Papers
(The H4-Index of Expert Review of Anticancer Therapy is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?75
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence66
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review38
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia34
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma27
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects24
Current status and novel insights into the role of metastasectomy in the era of immunotherapy24
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review24
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs24
Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy23
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan22
Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma21
Progress in histology specific treatments in soft tissue sarcoma21
Progress in the development of tissue-based biomarkers for urothelial cancer21
Current management of familial adenomatous polyposis19
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis17
Primary effusion lymphoma: therapeutic strategies targeting viral and cellular mechanisms17
2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma17
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer17
0.082787036895752